文献速递急性肾损伤

COVID-19住院患者尿液生物标志物的预后意义

Prognostic Significance of Urinary Biomarkers in Patients Hospitalized With COVID-19.
PubMed 文献 · Am J Kidney Dis · 2021-10-25

这项前瞻性队列研究纳入153例COVID-19住院患者,发现尿NGAL、MCP-1和KIM-1水平升高与60天内复合肾脏不良结局风险增加相关,而尿EGF水平升高与风险降低相关,生物标志物组合可提高判别能力。

要点

  • 尿NGAL、MCP-1、KIM-1升高与COVID-19住院患者不良肾脏结局风险增加独立相关。
  • 尿EGF升高与不良肾脏结局风险降低相关。
  • 部分无临床AKI患者尿损伤标志物已升高,提示亚临床AKI。

核心结论

  • 尿液生物标志物与COVID-19住院患者的不良肾脏结局相关,可能有助于监测肾脏病进展与恢复。

研究设计与样本

  • 前瞻性队列研究,纳入2020年4月至6月期间2家学术医疗中心的153例COVID-19住院患者。

主要发现

  • 153例中24例(15.7%)发生主要复合结局(KDIGO 3期AKI、需透析或入院60天内死亡)。
  • 尿NGAL每升高2倍,主要结局风险HR为1.34(95%CI 1.14-1.57)。
  • 尿MCP-1每升高2倍,主要结局风险HR为1.42(95%CI 1.09-1.84)。
  • 尿KIM-1每升高2倍,主要结局风险HR为2.03(95%CI 1.38-2.99)。
  • 尿EGF每升高2倍,主要结局风险HR为0.61(95%CI 0.47-0.79)。

关键数值与推荐

  • 主要复合结局定义为KDIGO 3期AKI、需透析或入院60天内死亡。
  • 单个生物标志物判别能力中等,生物标志物组合可改善对主要结局的判别。
  • COVID-19患者肾损伤生物标志物升高程度与其他临床AKI场景相当。
  • 基于血肌酐未达临床AKI标准的患者中,损伤标志物升高提示亚临床AKI。

临床怎么用

  • 可考虑检测尿NGAL、MCP-1、KIM-1和EGF以辅助评估COVID-19住院患者肾脏不良结局风险。

局限性

  • 样本量小,复合结局事件数少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Acute kidney injury (AKI) is common in patients with coronavirus disease 2019 (COVID-19) and associated with poor outcomes. Urinary biomarkers have been associated with adverse kidney outcomes in other settings and may provide additional prognostic information in patients with COVID-19. We investigated the association between urinary biomarkers and adverse kidney outcomes among patients hospitalized with COVID-19. STUDY DESIGN: Prospective cohort study. SETTING & PARTICIPANTS: Patients hospitalized with COVID-19 (n=153) at 2 academic medical centers between April and June 2020. EXPOSURE: 19 urinary biomarkers of injury, inflammation, and repair. OUTCOME: Composite of KDIGO (Kidney Disease: Improving Global Outcomes) stage 3 AKI, requirement for dialysis, or death within 60 days of hospital admission. We also compared various kidney biomarker levels in the setting of COVID-19 versus other common AKI settings. ANALYTICAL APPROACH: Time-varying Cox proportional hazards regression to associate biomarker level with composite outcome. RESULTS: Out of 153 patients, 24 (15.7%) experienced the primary outcome. Twofold higher levels of neutrophil gelatinase-associated lipocalin (NGAL) (HR, 1.34 [95% CI, 1.14-1.57]), monocyte chemoattractant protein (MCP-1) (HR, 1.42 [95% CI, 1.09-1.84]), and kidney injury molecule 1 (KIM-1) (HR, 2.03 [95% CI, 1.38-2.99]) were associated with highest risk of sustaining primary composite outcome. Higher epidermal growth factor (EGF) levels were associated with a lower risk of the primary outcome (HR, 0.61 [95% CI, 0.47-0.79]). Individual biomarkers provided moderate discrimination and biomarker combinations improved discrimination for the primary outcome. The degree of kidney injury by biomarker level in COVID-19 was comparable to other settings of clinical AKI. There was evidence of subclinical AKI in COVID-19 patients based on elevated injury biomarker level in patients without clinical AKI defined by serum creatinine. LIMITATIONS: Small sample size with low number of composite outcome events. CONCLUSIONS: Urinary biomarkers are associated with adverse kidney outcomes in patients hospitalized with COVID-19 and may provide valuable information to monitor kidney disease progression and recovery.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Menez S, Moledina DG, Thiessen-Philbrook H, et al. Prognostic Significance of Urinary Biomarkers in Patients Hospitalized With COVID-19. Am J Kidney Dis. 2021. PMID: 34710516. doi:10.1053/j.ajkd.2021.09.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。